The prevalence of overweight and obesity among patients with type 2 diabetes is extremely high. Data from two national surveys indicate that 28 % of individuals with diabetes were overweight and 59 % were obese. 1 Furthermore, a rise in body mass index (BMI) is directly correlated to an increased risk for diabetes. [2] [3] [4] The prevalence of type 2 diabetes is three to seven times higher in obese adults than in those of normal weight, and adults with a BMI >35 kg/m 2 are 20 times more likely to develop diabetes than those with a BMI between 18.5 and 24.9 kg/m 2 . 5, 6 Prediabetes and the metabolic syndrome are also associated with obesity. 7 Obesity is not only associated with an increased risk for developing type 2 diabetes but also an elevated probability of developing microvascular, 8 neuropathic, 8, 9 and cardiovascular 10,11 complications associated with the disease.
US ENDOCRINOLOGY
The American Diabetes Association (ADA) guidelines currently recommend a glycemic goal of glycated hemoglobin (HbA 1c ) <7.0 %. 23 However, they recommend that glucose goals should be individualized for patient depending on various risk factors. Glycemic goals present a challenge to the obese patient with diabetes, as improvement in glycemic control has been linked to weight gain due to the reduction in glycosuria associated with diabetes therapy. 24 Weight gain has been associated with both insulin and oral anti-diabetic therapies (see Table 1 ). 20, [25] [26] [27] [28] [29] As diabetes progresses, increasing b-cell dysfunction and insulin resistance necessitate the administration of higher dosages of insulin, or the addition of insulin to pharmacologic regimes that promote weight gain. A vicious circle may ensue. Strategies to overcome insulin-associated weight gain include increasing insulin sensitivity through diet and exercise, enabling dose reductions, or by the use of co-medications, such as pramlintide or metformin. 30 Newer, long-lasting basal insulin analogs, such as insulin detemir, are associated with lower levels of weight gain compared with shorter-acting insulin formulations. 31 Most oral anti-diabetic agents have been associated either with weight gain (thiazolidinediones, 25 sulfonylureas, 28 
) or are weight-neutral (alpha-glucosidase inhibitors; 32 dipeptidyl peptidase-IV inhibitors, 33 bile acid sequestrants 34 ). Metformin has been associated with beneficial effects on weight in type 2 diabetes, 35, 36 although a Cochrane review concluded that it is weight-neutral. 37 Modest weight loss has consistently been observed in clinical studies of glucagon-like peptide 1 (GLP-1) agonists in type 2 diabetes. 38 The addition of GLP-1 agonists to insulin therapy in obese patients with diabetes improves both glycemic control and weight. 39 The beneficial effect on weight is thought to be mediated by central regulation of feeding 40 and delayed gastric emptying, promoting early satiety. 41 Sodium-glucose co-transporter 2 (SGLT2) inhibitors, the newest class of diabetic medications, have also been associated with favorable effects on bodyweight, 42 resulting from an initial osmotic diuresis, and in the long term from increased urinary excretion of glucose.
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Impact of Treating Obesity in Diabetes
Numerous studies have demonstrated that weight loss in patients with diabetes results in improvement in glycemic control. 44 loss in a clinically representative obese population. 48 There is therefore a strong rationale for the use of anti-obesity drugs in overweight and obese patients with type 2 diabetes.
Anti-obesity Treatment Options in Diabetes
Lifestyle interventions should be undertaken before initiating drug therapy in obese patients with diabetes. These should include reductions in caloric intake of 500-1,000 calories per day, increases in physical activity, and changes in health behavior. Lifestyle interventions have proved successful in the prevention of diabetes, 47, 49 as well as in achieving weight loss in patients with type 2 diabetes. The Look AHEAD trial randomly assigned 5,145 overweight or obese patients with type 2 diabetes to participate in an intensive lifestyle intervention or to receive diabetes support and education. After a median follow-up of 9.6 years, weight loss was greater in the intervention group than in the control group throughout the study (8.6 % versus 0.7 % at 1 year; 6.0 % versus 3.5 % at study end). The intensive lifestyle intervention also produced greater reductions in HbA 1c . However, the trial was stopped early for futility after failing to meet its primary endpoint of reduction in the rate of cardiovascular events. 
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Bariatric surgery is an effective treatment for obesity in the prevention 53 and management of diabetes, and has resulted in rapid improvements in glycemic parameters 54, 55 but is associated with a risk for postoperative complications, including death, as well as being expensive and requiring specialist facilities. It is therefore unlikely to become a first-line treatment strategy for the majority of patients with diabetes and obesity. The Bariatric Physicians recommend that drug therapy is part of an overall strategy for managing overweight and obesity, which should include appropriate recommendations for diet, physical activity, and behavior therapy. 57, 58 Anti-obesity medications have been successfully employed in the management of obese patients with diabetes. 59 However, obesity is a complex disorder, and there is broad variability in the weight-loss response to all therapies for obesity including surgery, lifestyle interventions, and pharmacotherapy. Genome-wide association studies have identified numerous associated genes, 60, 61 suggesting that multiple mechanisms are involved in obesity. Furthermore, inflammation plays a major role in obesity. Studies have identified an imbalance between the levels of proinflammatory cytokines, such as interleukins and tumor necrosis factors, and the levels of anti-inflammatory cytokines. 62, 63 It is therefore unlikely that a single drug will be effective in all cases and there is a need for a range of anti-obesity therapies with differing mechanisms of action. Sources: Flegal 1998, 97 Flegal 2002, 98 Flegal 2010, 99 Flegal 2012, 100 Harris 1998, 101 Orlistat is associated with moderate weight loss 48 
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The most common AEs associated with lorcaserin are headache, nausea, dizziness, fatigue, dry mouth, and constipation. 75, 77 In the BLOOM-DM study, headache was reported in 14.5 % and 16.8% of the BID and QD lorcaserin groups, respectively; back pain was reported in 11.7 % and 8.4 % of the BID and QD lorcaserin groups, respectively; however, most were mild and self-limiting. 75 Concerns have been expressed in terms of the risk for valvulopathy associated with activation of the serotonin 2B (5-HT2B) receptors on cardiac interstitial cells; an association with valvulopathy resulted in the withdrawal of fenfluramine and dexfenfluramine from the market. 72 However, data from in vitro assays indicated that lorcaserin at recommended doses is unlikely to activate the 5-HT2B receptor. 78 Furthermore, among 2,472 patients evaluated at 1 year and 1,127 evaluated at 2 years in the BLOOM study, the rate of cardiac valvulopathy was not increased with the use of lorcaserin. 75 In the BLOOM-DM study, higher rates of valvulopathy were seen in lorcaserin-treated patients (2.5 % on lorcaserin BID; 3.9 % on lorcaserin QD) versus placebo (1.9 %) group; however, this was considered to be due to the unusually low rate of valvulopathy in the placebo group. Prescribing information recommends discontinuation if 5 % weight loss is not achieved by week 12, or if signs or symptoms of valvular heart disease develop. dysgeusia, depression-related symptoms, and anxiety-related symptoms in 5-10 %. 76 Safety concerns about PHEN/TPM ER include teratogenicity and elevation in resting heart rate. 82 However, a large populationbased cohort study (n=837,795) did not find an increased incidence of birth defects. 83 Other concerns include the risk for metabolic acidosis, glaucoma, and psychiatric and cognitive AEs. The safety profile of liraglutide is acceptable; the most common AEs were related to the gastrointestinal system and diminished over time. 86 In 2011, the FDA advisory panel issued a safety warning regarding the risk for thyroid C-cell tumors and pancreatitis with liraglutide, 87 following the discovery that long-term liraglutide exposure is associated with C-cell carcinoma and thyroid C-cell focal hyperplasia in rodents. 88 However, a recent study suggested that GLP1 receptor agonist-induced C-cell responses in rodents may not be relevant to primates. 89 Concern has also been raised about the potential for pancreatitis; however, liraglutide did not induce pancreatitis in mice, rats, or monkeys when dosed for up to 2 years and at exposure levels up to 60 times higher than in humans. 90 Other impediments to the widespread use of liraglutide include its relatively high cost and the fact that it administered by intramuscular injection, reducing its acceptability to patients. There is a need for long-term safety data on these medications, in order to dispel fears associated with the safely of anti-obesity medications and increase their clinical utility. An analysis of data from the National Health and Nutritional Examination Survey in 2007-8 found that 45.4 % of the sample population were eligible for anti-obesity treatment. However, among these, only 0.6 % were taking anti-obesity drugs. 96 Reasons for this low usage may include concerns over the limited effectiveness and safety of previously available drugs.
Summary and Concluding Remarks
The twin epidemics of diabetes and obesity continue to rise and intervention is required to prevent a global public health crisis. A large body of clinical data supports the treatment of obesity as a management strategy in type 2 diabetes (see Figure 1) . [97] [98] [99] [100] [101] [102] [103] [104] [105] Lifestyle modification focused on diet and physical activity should be an essential component of weight-management interventions. Anti-obesity medications also play a role in weight management, providing modest additional fat loss to that achieved by lifestyle modification alone, improving quality of life (QoL) and showing improvements in glycemic parameters in patients with type 2 diabetes. However, obesity is a heterogeneous condition: the genetic and pathophysiologic factors underlying obesity are highly variable between individuals and, therefore, the clinical response to anti-obesity medication may also vary. There is therefore a need for need for a variety of drugs with differing mechanisms in the management of obesity in type 2 diabetes in order to achieve individualized and optimized therapy. meaningful improvement in QoL. However, the relatively high dropout rates observed in these trials suggest that compliance may be a limiting factor in day-to-day use of these therapies. Despite these concerns, evidence to date suggests that new anti-obesity medications have been well accepted by patients and, in conjunction with lifestyle modification, offer an effective alternative to bariatric surgery in patients with type 2 diabetes. n
